October 2022 - 4D Lifetec and Medicover sign partnership agreement to commercialize 4D Lifetest™ Lung Dx liquid biopsy assay in Europe

The collaboration will start with a pilot launch, where Medicover's diagnostic laboratory in Basel will be equipped and trained by 4D Lifetec and subsequently take over the diagnostic care of the first Swiss customers. Full launch is expected by the end of Q4 2022. The expansion of the care network into other European countries is envisaged from 2023 onwards. 

4D Lifetec AG became the pioneering company in non-genomic liquid biopsy cancer diagnostic. 4D Lifetest™ Lung Dx is the company’s flagship product and the first IVD blood liquid biopsy assay to non-invasively assess lung cancer formation at its earliest stage. This diagnostic information is based on the company’s unique transformational biomarker and marks a breakthrough progress to tackle the catastrophic mortality rates of lung cancer patients and protect benign patients from the invasive stress of frequently repeated surveillance diagnostics. 4D Lifetec starts to sell to central diagnostic laboratories (CLIA) initially in Europe and later in the U.S., targeting the oncology and pulmonary departments of leading hospital centers and key opinion leaders (KOL). With Medicover a first leading international CRO could be contracted as commercial partner.

Medicover is a leading international healthcare and diagnostic services provider specialized in providing diagnostic and healthcare services, focusing on markets mainly in Central and Eastern Europe and India. With its Diagnostic Services Division, Medicover provides a broad range of laboratory testing in all major clinical pathology areas. The business is conducted through a network of 99 laboratories, 852 blood-drawing points (BDPs) and 24 clinics.